Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study^*

References

• Romero R, Lockwood C, Oyarzun E, et al. Toxemia: new concepts in an old disease. Semin Perinatol 1988;12:302–23
   PubMed Web of Science ®Google Scholar
• Romero R. The child is the father of the man. Prenat Neonat Med 1996;1:8–11
   Google Scholar
• Di Renzo GC. The great obstetrical syndromes. J Matern Fetal Neonatal Med 2009;22:633–5
   PubMed Web of Science ®Google Scholar
• Romero R. Prenatal medicine: the child is the father of the man. 1996. J Matern Fetal Neonatal Med 2009;22:636–9
   PubMed Web of Science ®Google Scholar
• Mattar F, Sibai BM. Eclampsia. VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol 2000;182:307–12
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592–4
   PubMed Web of Science ®Google Scholar
• Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005;46:1243–9
   PubMed Web of Science ®Google Scholar
• von Dadelszen P, Menzies J, Magee LA. The complications of hypertension in pregnancy. Minerva Med 2005;96:287–302
   PubMedGoogle Scholar
• Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066–74
   PubMed Web of Science ®Google Scholar
• Sibai BM. Hypertensive disorders of pregnancy: the United States perspective. Curr Opin Obstet Gynecol 2008;20:102–6
   PubMed Web of Science ®Google Scholar
• Clark SL, Belfort MA, Dildy GA, et al. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 2008;199:36 e31–5; discussion 91–32 e37–11
   Web of Science ®Google Scholar
• Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol 2009;113:1299–306
   PubMed Web of Science ®Google Scholar
• Habli M, Eftekhari N, Wiebracht E, et al. Long-term maternal and subsequent pregnancy outcomes 5 years after hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Am J Obstet Gynecol 2009;201:385 e381–5
   Web of Science ®Google Scholar
• Berg CJ, Mackay AP, Qin C, et al. Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005. Obstet Gynecol 2009;113:1075–81
   PubMed Web of Science ®Google Scholar
• Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011;25:391–403
   PubMed Web of Science ®Google Scholar
• Cruz MO, Gao W, Hibbard JU. Obstetrical and perinatal outcomes among women with gestational hypertension, mild preeclampsia, and mild chronic hypertension. Am J Obstet Gynecol 2011;205:260 e261–9
   Web of Science ®Google Scholar
• Thornton C, Dahlen H, Korda A, et al. The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000-2008. Am J Obstet Gynecol 2013;208:476 e471–5
   Web of Science ®Google Scholar
• Vrachnis N, Vlachadis N, Iliodromiti Z. The incidence of preeclampsia and eclampsia in Australia: 2000 through 2008. Am J Obstet Gynecol 2014;210:174–4
   PubMed Web of Science ®Google Scholar
• Nakimuli A, Chazara O, Byamugisha J, et al. Pregnancy, parturition and preeclampsia in women of African ancestry. Am J Obstet Gynecol 2014;210:510–20
   PubMed Web of Science ®Google Scholar
• Witlin AG, Saade GR, Mattar F, et al. Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2000;182:607–11
   PubMed Web of Science ®Google Scholar
• Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877–90
   PubMed Web of Science ®Google Scholar
• Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 2006;30:16–19
   PubMed Web of Science ®Google Scholar
• Ganzevoort W, Rep A, de Vries JI, et al. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006;195:495–503
   PubMed Web of Science ®Google Scholar
• Habli M, Levine RJ, Qian C, et al. Neonatal outcomes in pregnancies with preeclampsia or gestational hypertension and in normotensive pregnancies that delivered at 35, 36, or 37 weeks of gestation. Am J Obstet Gynecol 2007;197:406 e401–7
   Web of Science ®Google Scholar
• Chappell LC, Enye S, Seed P, et al. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 2008;51:1002–9
   PubMed Web of Science ®Google Scholar
• Langenveld J, Ravelli AC, van Kaam AH, et al. Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry. Am J Obstet Gynecol 2011;205:540 e541–7
   Web of Science ®Google Scholar
• Belghiti J, Kayem G, Tsatsaris V, et al. Benefits and risks of expectant management of severe preeclampsia at less than 26 weeks gestation: the impact of gestational age and severe fetal growth restriction. Am J Obstet Gynecol 2011;205:465 e461–6
   Web of Science ®Google Scholar
• Brosens I, Robertson WB, Dixon HG. The physiological response of the vessels of the placental bed to normal pregnancy. J Pathol Bacteriol 1967;93:569–79
   PubMedGoogle Scholar
• Brosens I, Renaer M. On the pathogenesis of placental infarcts in pre-eclampsia. J Obstet Gynaecol Br Commonw 1972;79:794–9
   PubMedGoogle Scholar
• Khong TY, De Wolf F, Robertson WB, et al. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049–59
   PubMedGoogle Scholar
• Pijnenborg R, Brosens I. Deep trophoblast invasion and spiral artery remodeling. In: Pijnenborg R, Brosens I, Romero R, eds. Placental bed disorders. Cambridge: Cambridge University Press; 2010;97–108
   Google Scholar
• Romero R, Kusanovic JP, Kim CJ. Disorders of the placental bed in the genesis of the great obstetrical syndromes In: Pijnenborg R, Brosens I, Romero R, eds. Placental bed disorders. Cambridge: Cambridge University Press; 2010;271–89
   Google Scholar
• Brosens I, Pijnenborg R, Vercruysse L, et al. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 2011;204:193–201
   PubMed Web of Science ®Google Scholar
• Romero R, Kusanovic JP, Chaiworapongsa T, et al. Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best Pract Res Clin Obstet Gynaecol 2011;25:313–27
   PubMed Web of Science ®Google Scholar
• Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405–23
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555–63
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348–51
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541–7; discussion 1547–50
   PubMed Web of Science ®Google Scholar
• Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG 2004;111:298–302
   PubMed Web of Science ®Google Scholar
• Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004;145:4838–45
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3–18
   PubMed Web of Science ®Google Scholar
• Ahmad S, Ahmed A. Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis. Endothelium 2005;12:89–95
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–9
   PubMed Web of Science ®Google Scholar
• Vatten LJ, Eskild A, Nilsen TI, et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007;196:239 e231–6
   Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Gotsch F, et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 2008;21:41–52
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279–87
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38
   PubMed Web of Science ®Google Scholar
• Stepan H. Angiogenic factors and pre-eclampsia: an early marker is needed. Clin Sci (Lond) 2009;116:231–2
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kusanovic JP, et al. Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol 2010;35:155–62
   PubMed Web of Science ®Google Scholar
• Silasi M, Cohen B, Karumanchi SA, et al. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010;37:239–53
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187–207
   PubMed Web of Science ®Google Scholar
• Ogge G, Chaiworapongsa T, Romero R, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med 2011;39:641–52
   PubMed Web of Science ®Google Scholar
• Soto E, Romero R, Kusanovic JP, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2012;25:498–507
   PubMed Web of Science ®Google Scholar
• Hagmann H, Thadhani R, Benzing T, et al. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012;58:837–45
   PubMed Web of Science ®Google Scholar
• Weed S, Bastek JA, Anton L, et al. Examining the correlation between placental and serum placenta growth factor in preeclampsia. Am J Obstet Gynecol 2012;207:140 e141–6
   Web of Science ®Google Scholar
• Weissgerber TL, Roberts JM, Jeyabalan A, et al. Haptoglobin phenotype, angiogenic factors, and preeclampsia risk. Am J Obstet Gynecol 2012;206:358 e310–58
   Web of Science ®Google Scholar
• Rana S, Cerdeira AS, Wenger J, et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One 2012;7:e48259
   PubMed Web of Science ®Google Scholar
• McElrath TF, Lim KH, Pare E, et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012;207:407 e401–7
   Web of Science ®Google Scholar
• Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121–31
   PubMed Web of Science ®Google Scholar
• Goel A, Rana S. Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens 2013;22:643–50
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014;63:346–52
   PubMed Web of Science ®Google Scholar
• Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med 2013;41:511–16
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013;208:287 e281–7 e215
   Web of Science ®Google Scholar
• Moore Simas TA, Crawford SL, Bathgate S, et al. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. J Matern Fetal Neonatal Med 2014;27:1038–48
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med 2014;27:132–44
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014;63:346–52
   PubMed Web of Science ®Google Scholar
• Sacks GP, Studena K, Sargent K, et al. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80–6
   PubMed Web of Science ®Google Scholar
• Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499–506
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta 2000;21:597–602
   PubMed Web of Science ®Google Scholar
• Gervasi MT, Chaiworapongsa T, Pacora P, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001;185:792–7
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response–a review. Placenta 2003;24:S21–7
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004;24:565–70
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 2008;29(Suppl A):S73–7
   PubMed Web of Science ®Google Scholar
• Redman CW, Tannetta DS, Dragovic RA, et al. Review: does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 2012;33 Suppl:S48–54
   PubMed Web of Science ®Google Scholar
• Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200–4
   PubMed Web of Science ®Google Scholar
• Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4:700–8
   PubMed Web of Science ®Google Scholar
• Friedman SA, Schiff E, Emeis JJ, et al. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995;172:202–3
   PubMed Web of Science ®Google Scholar
• Lyall F, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod 1996;1:107–16
   PubMedGoogle Scholar
• Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:5–15
   PubMedGoogle Scholar
• Taylor RN, de Groot CJ, Cho YK, et al. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:17–31
   PubMedGoogle Scholar
• Cindrova-Davies T. Gabor Than Award Lecture 2008: pre-eclampsia - from placental oxidative stress to maternal endothelial dysfunction. Placenta 2009;30 Suppl A:S55–65
   PubMed Web of Science ®Google Scholar
• Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999;222:222–35
   PubMed Web of Science ®Google Scholar
• Myatt L, Kossenjans W, Sahay R, et al. Oxidative stress causes vascular dysfunction in the placenta. J Matern Fetal Med 2000;9:79–82
   PubMedGoogle Scholar
• Vaughan JE, Walsh SW. Oxidative stress reproduces placental abnormalities of preeclampsia. Hypertens Pregn 2002;21:205–23
   PubMed Web of Science ®Google Scholar
• Burton GJ, Yung HW, Cindrova-Davies T, et al. Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta 2009;30 Suppl A:S43–8
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang GY, Wang J, et al. A novel bridge between oxidative stress and immunity: the interaction between hydrogen peroxide and human leukocyte antigen G in placental trophoblasts during preeclampsia. Am J Obstet Gynecol 2012;206:447 e447–16
   Web of Science ®Google Scholar
• Lian IA, Loset M, Mundal SB, et al. Increased endoplasmic reticulum stress in decidual tissue from pregnancies complicated by fetal growth restriction with and without pre-eclampsia. Placenta 2011;32:823–9
   PubMed Web of Science ®Google Scholar
• Rakoczi I, Tallian F, Bagdany S, et al. Platelet life-span in normal pregnancy and pre-eclampsia as determined by a non-radioisotope technique. Thromb Res 1979;15:553–6
   PubMed Web of Science ®Google Scholar
• Socol ML, Weiner CP, Louis G, et al. Platelet activation in preeclampsia. Am J Obstet Gynecol 1985;151:494–7
   PubMed Web of Science ®Google Scholar
• Csaicsich P, Deutinger J, Tatra G. Platelet specific proteins (beta-thromboglobulin and platelet factor 4) in normal pregnancy and in pregnancy complicated by preeclampsia. Arch Gynecol Obstet 1989;244:91–5
   PubMed Web of Science ®Google Scholar
• Fitzgerald DJ, Rocki W, Murray R, et al. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet 1990;335:751–4
   PubMed Web of Science ®Google Scholar
• Ahmed Y, van Iddekinge B, Paul C, et al. Retrospective analysis of platelet numbers and volumes in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1993;100:216–20
   PubMedGoogle Scholar
• Cunningham FG, Pritchard JA. Hematologic considerations of pregnancy-induced hypertension. Semin Perinatol 1978;2:29–38
   PubMed Web of Science ®Google Scholar
• Weenink GH, Treffers PE, Vijn P, et al. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984;148:1092–7
   PubMed Web of Science ®Google Scholar
• de Boer K, ten Cate JW, Sturk A, et al. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989;160:95–100
   PubMed Web of Science ®Google Scholar
• Cadroy Y, Grandjean H, Pichon J, et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993;100:416–20
   PubMedGoogle Scholar
• Chaiworapongsa T, Yoshimatsu J, Espinoza J, et al. Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med 2002;11:362–7
   PubMedGoogle Scholar
• Dekker G. Prothrombotic mechanisms in preeclampsia. Thromb Res 2005;115:17–21
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Kim SS, et al. Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med 2008;21:345–55
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Hoppensteadt D, et al. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med 2008;21:855–69
   PubMed Web of Science ®Google Scholar
• Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945–52
   PubMed Web of Science ®Google Scholar
• Wallukat G, Neichel D, Nissen E, et al. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can J Physiol Pharmacol 2003;81:79–83
   PubMed Web of Science ®Google Scholar
• LaMarca B. Progress toward identifying potential markers for preeclampsia: role of agonistic autoantibody to the angiotensin II type I receptor. Hypertension 2010;55:236–7
   PubMed Web of Science ®Google Scholar
• Parrish MR, Murphy SR, Rutland S, et al. The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens 2010;23:911–16
   PubMed Web of Science ®Google Scholar
• Siddiqui AH, Irani RA, Blackwell SC, et al. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010;55:386–93
   PubMed Web of Science ®Google Scholar
• Irani RA, Zhang Y, Zhou CC, et al. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling. Hypertension 2010;55:1246–53
   PubMed Web of Science ®Google Scholar
• LaMarca B, Wallace K, Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol 2011;11:175–9
   PubMed Web of Science ®Google Scholar
• LaMarca B, Parrish MR, Wallace K. Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia. Gend Med 2012;9:139–46
   PubMed Web of Science ®Google Scholar
• Xia Y, Kellems RE. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res 2013;113:78–87
   PubMed Web of Science ®Google Scholar
• Herse F, LaMarca B. Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol 2013;69:413–18
   PubMed Web of Science ®Google Scholar
• Garner PR, D'Alton ME, Dudley DK, et al. Preeclampsia in diabetic pregnancies. Am J Obstet Gynecol 1990;163:505–8
   PubMed Web of Science ®Google Scholar
• Berkowitz GS, Roman SH, Lapinski RH, et al. Maternal characteristics, neonatal outcome, and the time of diagnosis of gestational diabetes. Am J Obstet Gynecol 1992;167:976–82
   PubMed Web of Science ®Google Scholar
• Greco P, Loverro G, Selvaggi L. Does gestational diabetes represent an obstetrical risk factor? Gynecol Obstet Invest 1994;37:242–5
   PubMed Web of Science ®Google Scholar
• Kaaja R, Tikkanen MJ, Viinikka L, et al. Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women. Obstet Gynecol 1995;85:353–6
   PubMed Web of Science ®Google Scholar
• Kaaja R. Insulin resistance syndrome in preeclampsia. Semin Reprod Endocrinol 1998;16:41–6
   PubMedGoogle Scholar
• Joffe GM, Esterlitz JR, Levine RJ, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1998;179:1032–7
   PubMed Web of Science ®Google Scholar
• Lorentzen B, Birkeland KI, Endresen MJ, et al. Glucose intolerance in women with preeclampsia. Acta Obstet Gynecol Scand 1998;77:22–7
   PubMed Web of Science ®Google Scholar
• Kaaja R, Laivuori H, Laakso M, et al. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism 1999;48:892–6
   PubMed Web of Science ®Google Scholar
• Caruso A, Ferrazzani S, Paradisi G. Insulin resistance and preeclampsia: is there a relationship? Am J Obstet Gynecol 1999;181:768–9
   PubMed Web of Science ®Google Scholar
• Nisell H, Erikssen C, Persson B, et al. Is carbohydrate metabolism altered among women who have undergone a preeclamptic pregnancy? Gynecol Obstet Invest 1999;48:241–6
   PubMed Web of Science ®Google Scholar
• Solomon CG, Seely EW. Brief review: hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension 2001;37:232–9
   PubMed Web of Science ®Google Scholar
• Thadhani R, Ecker JL, Mutter WP, et al. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension 2004;43:988–92
   PubMed Web of Science ®Google Scholar
• Emery SP, Levine RJ, Qian C, et al. Twenty-four-hour urine insulin as a measure of hyperinsulinaemia/insulin resistance before onset of pre-eclampsia and gestational hypertension. BJOG 2005;112:1479–85
   PubMed Web of Science ®Google Scholar
• Parretti E, Lapolla A, Dalfra M, et al. Preeclampsia in lean normotensive normotolerant pregnant women can be predicted by simple insulin sensitivity indexes. Hypertension 2006;47:449–53
   PubMed Web of Science ®Google Scholar
• Roberts JM, Gammill H. Insulin resistance in preeclampsia. Hypertension 2006;47:341–2
   PubMed Web of Science ®Google Scholar
• Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006;195:40–9
   PubMed Web of Science ®Google Scholar
• Mazar RM, Srinivas SK, Sammel MD, et al. Metabolic score as a novel approach to assessing preeclampsia risk. Am J Obstet Gynecol 2007;197:411 e411–15
   Web of Science ®Google Scholar
• Mazaki-Tovi S, Romero R, Vaisbuch E, et al. Maternal serum adiponectin multimers in preeclampsia. J Perinat Med 2009;37:349–63
   PubMed Web of Science ®Google Scholar
• Catalano PM. Obesity, insulin resistance, and pregnancy outcome. Reproduction 2010;140:365–71
   PubMed Web of Science ®Google Scholar
• Hauth JC, Clifton RG, Roberts JM, et al. Maternal insulin resistance and preeclampsia. Am J Obstet Gynecol 2011;204:327 e321–6
   Google Scholar
• Bytautiene E, Tamayo E, Kechichian T, et al. Prepregnancy obesity and sFlt1-induced preeclampsia in mice: developmental programming model of metabolic syndrome. Am J Obstet Gynecol 2011;204:398 e391–8
   Web of Science ®Google Scholar
• Lynch AM, Eckel RH, Murphy JR, et al. Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol 2012;206:428 e421–8
   Web of Science ®Google Scholar
• Stekkinger E, Scholten R, van der Vlugt MJ, et al. Metabolic syndrome and the risk for recurrent pre-eclampsia: a retrospective cohort study. BJOG 2013;120:979–86
   PubMed Web of Science ®Google Scholar
• Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013;209:544 e541–44 e512
   Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54
   PubMed Web of Science ®Google Scholar
• Lebreton JP, Joisel F, Raoult JP, et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118–29
   PubMed Web of Science ®Google Scholar
• Daveau M, Christian D, Julen N, et al. The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 1988;241:191–4
   PubMed Web of Science ®Google Scholar
• Daveau M, Davrinche C, Djelassi N, et al. Partial hepatectomy and mediators of inflammation decrease the expression of liver alpha 2-HS glycoprotein gene in rats. FEBS Lett 1990;273:79–81
   PubMed Web of Science ®Google Scholar
• Wang H, Sama AE. Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med 2012;12:625–33
   PubMed Web of Science ®Google Scholar
• Molvarec A, Prohaszka Z, Nagy B, et al. Association of increased serum heat shock protein 70 and C-reactive protein concentrations and decreased serum alpha(2)-HS glycoprotein concentration with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. J Reprod Immunol 2007;73:172–9
   PubMed Web of Science ®Google Scholar
• Molvarec A, Kalabay L, Derzsy Z, et al. Preeclampsia is associated with decreased serum alpha(2)-HS glycoprotein (fetuin-A) concentration. Hypertens Res 2009;32:665–9
   PubMed Web of Science ®Google Scholar
• Johnstone ED, Sawicki G, Guilbert L, et al. Differential proteomic analysis of highly purified placental cytotrophoblasts in pre-eclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense. Proteomics 2011;11:4077–84
   PubMed Web of Science ®Google Scholar
• Park J, Cha DH, Lee SJ, et al. Discovery of the serum biomarker proteins in severe preeclampsia by proteomic analysis. Exp Mol Med 2011;43:427–35
   PubMed Web of Science ®Google Scholar
• Gomez LM, Anton L, Srinivas SK, et al. Effects of increased fetuin-A in human trophoblast cells and associated pregnancy outcomes. Am J Obstet Gynecol 2012;207:e1–8
   PubMed Web of Science ®Google Scholar
• Gomez LM. Understanding the effects of fetuin-A in pregnancy. Med J Obstet Gynecol 2013;1:1010
   Google Scholar
• Pedersen KO. Fetuin, a new globulin isolated from serum. Nature 1944;154:575
   Google Scholar
• Dziegielewska KM, Brown WM, Casey SJ, et al. The complete cDNA and amino acid sequence of bovine fetuin. Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily. J Biol Chem 1990;265:4354–7
   PubMed Web of Science ®Google Scholar
• Li W, Zhu S, Li J, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 2011;6:e16945
   PubMed Web of Science ®Google Scholar
• van Oss CJ, Gillman CF, Bronson PM, et al. Opsonic properties of human serum alpha-2 hs glycoprotein. Immunol Commun 1974;3:329–35
   PubMed Web of Science ®Google Scholar
• Lewis JG, Andre CM. Enhancement of human monocyte phagocytic function by alpha 2HS glycoprotein. Immunology 1981;42:481–7
   PubMed Web of Science ®Google Scholar
• Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond) 2003;105:273–8
   PubMed Web of Science ®Google Scholar
• Auberger P, Falquerho L, Contreres JO, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989;58:631–40
   PubMed Web of Science ®Google Scholar
• Rauth G, Poschke O, Fink E, et al. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem 1992;204:523–9
   PubMedGoogle Scholar
• Srinivas PR, Wagner AS, Reddy LV, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993;7:1445–55
   PubMed Web of Science ®Google Scholar
• Mathews ST, Chellam N, Srinivas PR, et al. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol 2000;164:87–98
   PubMed Web of Science ®Google Scholar
• Mathews ST, Singh GP, Ranalletta M, et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002;51:2450–8
   PubMed Web of Science ®Google Scholar
• Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol 2013;9:144–52
   PubMed Web of Science ®Google Scholar
• Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012;18:1279–85
   PubMed Web of Science ®Google Scholar
• Chaemsaithong P, Romero R, Chaiworapongsa T, et al. Fetuin-A, a negative acute phase protein reactant, is decreased in preeclampsia. Am J Obstet Gynecol (Submitted). 2014
   Google Scholar
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159–67
   PubMed Web of Science ®Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785–99
   PubMed Web of Science ®Google Scholar
• Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163–8
   PubMed Web of Science ®Google Scholar
• Gonzalez RP, Gomez RM, Castro RS, et al. [A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000]. Rev Med Chil 2004;132:1155–65
   PubMed Web of Science ®Google Scholar
• Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–74
   PubMed Web of Science ®Google Scholar
• Douglas B, Maechler M, Bolker B. 2012. lme4: Linear mixed-effects models using S4 classes.R package version 0.999999-0. Available from: http://CRAN.R-project.org/package = lme4
   Google Scholar
• Vince GS, Starkey PM, Austgulen R, et al. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995;102:20–5
   PubMedGoogle Scholar
• Hamai Y, Fujii T, Yamashita T, et al. Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia. Am J Reprod Immunol 1997;38:89–93
   PubMed Web of Science ®Google Scholar
• Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998;40:102–11
   PubMed Web of Science ®Google Scholar
• Teran E, Escudero C, Moya W, et al. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet 2001;75:243–9
   PubMed Web of Science ®Google Scholar
• Serin IS, Ozcelik B, Basbug M, et al. Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2002;100:143–5
   PubMed Web of Science ®Google Scholar
• Velzing-Aarts FV, Muskiet FA, van der Dijs FP, et al. High serum interleukin-8 levels in afro-caribbean women with pre-eclampsia. Relations with tumor necrosis factor-alpha, duffy negative phenotype and von Willebrand factor. Am J Reprod Immunol 2002;48:319–22
   PubMed Web of Science ®Google Scholar
• Kocyigit Y, Atamer Y, Atamer A, et al. Changes in serum levels of leptin, cytokines and lipoprotein in pre-eclamptic and normotensive pregnant women. Gynecol Endocrinol 2004;19:267–73
   PubMed Web of Science ®Google Scholar
• Afshari JT, Ghomian N, Shameli A, et al. Determination of interleukin-6 and tumor necrosis factor-alpha concentrations in Iranian-Khorasanian patients with preeclampsia. BMC Pregn Childbirth 2005;5:14
   PubMedGoogle Scholar
• Huang X, Huang H, Dong M, et al. Serum and placental interleukin-18 are elevated in preeclampsia. J Reprod Immunol 2005;65:77–87
   PubMed Web of Science ®Google Scholar
• Jonsson Y, Ruber M, Matthiesen L, et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol 2006;70:83–91
   PubMed Web of Science ®Google Scholar
• Szarka A, Rigo J, Jr Lazar L, et al. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010;11:59
   PubMed Web of Science ®Google Scholar
• Xie C, Yao MZ, Liu JB, et al. A meta-analysis of tumor necrosis factor-alpha, interleukin-6, and interleukin-10 in preeclampsia. Cytokine 2011;56:550–9
   PubMed Web of Science ®Google Scholar
• Ozler A, Turgut A, Sak ME, et al. Serum levels of neopterin, tumor necrosis factor-alpha and Interleukin-6 in preeclampsia: relationship with disease severity. Eur Rev Med Pharmacol Sci 2012;16:1707–12
   PubMed Web of Science ®Google Scholar
• Soto E, Romero R, Richani K, et al. Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med 2010;23:646–57
   PubMed Web of Science ®Google Scholar
• Saito S, Umekage H, Sakamoto Y, et al. Increased T-helper-1-type immunity and decreased T-helper-2-type immunity in patients with preeclampsia. Am J Reprod Immunol 1999;41:297–306
   PubMed Web of Science ®Google Scholar
• Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, et al. T helper 1- and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1999;86:165–70
   PubMed Web of Science ®Google Scholar
• Darmochwal-Kolarz D, Rolinski J, Leszczynska-Goarzelak B, et al. The expressions of intracellular cytokines in the lymphocytes of preeclamptic patients. Am J Reprod Immunol 2002;48:381–6
   PubMed Web of Science ®Google Scholar
• Rein DT, Schondorf T, Gohring UJ, et al. Cytokine expression in peripheral blood lymphocytes indicates a switch to T(HELPER) cells in patients with preeclampsia. J Reprod Immunol 2002;54:133–42
   PubMed Web of Science ®Google Scholar
• Luppi P, Deloia JA. Monocytes of preeclamptic women spontaneously synthesize pro-inflammatory cytokines. Clin Immunol 2006;118:268–75
   PubMed Web of Science ®Google Scholar
• Naccasha N, Gervasi MT, Chaiworapongsa T, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. Am J Obstet Gynecol 2001;185:1118–23
   PubMed Web of Science ®Google Scholar
• Boij R, Svensson J, Nilsson-Ekdahl K, et al. Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 2012;68:258–70
   PubMed Web of Science ®Google Scholar
• Peracoli JC, Bannwart-Castro CF, Romao M, et al. High levels of heat shock protein 70 are associated with pro-inflammatory cytokines and may differentiate early- from late-onset preeclampsia. J Reprod Immunol 2013;100:129–34
   PubMed Web of Science ®Google Scholar
• Jahnen-Dechent W, Schinke T, Trindl A, et al. Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 1997;272:31496–503
   PubMed Web of Science ®Google Scholar
• Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357–66
   PubMed Web of Science ®Google Scholar
• Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005;67:2295–304
   PubMed Web of Science ®Google Scholar
• Roos M, Richart T, Kouznetsova T, et al. Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept 2009;154:39–43
   PubMed Web of Science ®Google Scholar
• Ford ML, Tomlinson LA, Smith ER, et al. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant 2010;25:1853–8
   PubMed Web of Science ®Google Scholar
• Jung JY, Hwang YH, Lee SW, et al. Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol Dial Transplant 2010;25:4041–8
   PubMed Web of Science ®Google Scholar
• Caglar K, Yilmaz MI, Saglam M, et al. Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 2007;83:392–7
   PubMed Web of Science ®Google Scholar
• Caglar K, Yilmaz MI, Saglam M, et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3:61–8
   PubMed Web of Science ®Google Scholar
• Tihtonen KM, Koobi T, Uotila JT. Arterial stiffness in preeclamptic and chronic hypertensive pregnancies. Eur J Obstet Gynecol Reprod Biol 2006;128:180–6
   PubMed Web of Science ®Google Scholar
• Kaihura C, Savvidou MD, Anderson JM, et al. Maternal arterial stiffness in pregnancies affected by preeclampsia. Am J Physiol Heart Circ Physiol 2009;297:H759–64
   PubMed Web of Science ®Google Scholar
• Hausvater A, Giannone T, Sandoval YH, et al. The association between preeclampsia and arterial stiffness. J Hypertens 2012;30:17–33
   PubMed Web of Science ®Google Scholar